InMed Pharmaceuticals Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation British Columbia, Canada
Business Address 1445-885 WEST GEORGIA ST., VANCOUVER, A1, V6C 3E8
Mailing Address 1445-885 WEST GEORGIA ST., VANCOUVER, A1, V6C 3E8
Phone (604) 669-7207
Fiscal Year End 0630
EIN 000000000
Financial Overview
FY2025
$12.09M
Stockholders' Equity
$-8.36
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | February 12, 2026 | View on SEC |
| 10-Q Quarterly financial report | February 11, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | January 20, 2026 | View on SEC |
| 4 Insider stock transaction report | December 19, 2025 | View on SEC |
| 4 Insider stock transaction report | December 19, 2025 | View on SEC |
| 4 Insider stock transaction report | December 19, 2025 | View on SEC |
| 4 Insider stock transaction report | December 19, 2025 | View on SEC |
| 4 Insider stock transaction report | December 19, 2025 | View on SEC |
| 4 Insider stock transaction report | December 19, 2025 | View on SEC |
| 4 Insider stock transaction report | December 19, 2025 | View on SEC |
Annual Reports
10-K September 23, 2025
- First-ever Phase 2 trial for cannabinol drug INM-755 (EB) showed safety and hinted at efficacy.
- Preclinical Alzheimer’s drug INM-901 demonstrates potential to target brain inflammation.
Material Events
8-K Legal Issue December 15, 2025
High Impact
- InMed Pharmaceuticals announced a potential "material negative impact" on its subsidiary, BayMedica Inc., due to new U.S. law H.R. 5371.
- The law, set to come into force on November 12, 2026, would prohibit certain aspects of BayMedica’s commercial business and its inventory of rare, non-intoxicating cannabinoids.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.